RNA-binding protein RBM38 inhibits colorectal cancer progression by partly and competitively binding to PTEN 3'UTR with miR-92a-3p.
PTEN
RBM38
RNA binding protein
colorectal cancer
miR-92a-3p
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
02
08
2021
received:
18
05
2021
accepted:
15
08
2021
pubmed:
29
8
2021
medline:
5
11
2021
entrez:
28
8
2021
Statut:
ppublish
Résumé
RNA-binding motif protein 38 (RBM38) belongs to the RNA recognition motif family of RNA-binding proteins (RBPs). RBM38 was previously identified to suppress tumorigenesis in colorectal cancer (CRC). RBM38 was also reported to bind to the 3'UTR of phosphatase and tensin homolog gene on chromosome 10 (PTEN), a tumor suppressor involved in many cellular processes, to stabilize PTEN transcripts. In the present study, we investigated the mechanisms underlying the regulation of RBM38 in CRC. Reverse transcription quantitative polymerase chain reaction and western blotting detected the expression of RBM38, PTEN, and miR-92a-3p. Colony formation, EdU, sphere formation, Transwell invasion, and in vivo assays examined the influence of RBM38 on CRC progression. Furthermore, RNA immunoprecipitation (RIP) assay determined the binding site of RBM38 on PTEN 3'UTR. The binding of miR-92a-3p or RBM38 on PTEN 3'UTR was assessed by luciferase reporter and RIP assays. We discovered that RBM38 was downregulated in CRC cells and tissues. RBM38 repressed CRC progression in vitro and in vivo. Furthermore, RBM38 upregulated and stabilized PTEN expression. Interestingly, the overexpression of PTEN reversely attenuated the promotion of RBM38 depletion on CRC progression. Additionally, RBM38 competed with miR-92a-3p in binding to PTEN 3'UTR. In conclusion, RBM38 inhibits CRC progression by competitively binding to PTEN 3'UTR with miR-92a-3p.
Substances chimiques
3' Untranslated Regions
0
MicroRNAs
0
RBM38 protein, human
0
RNA-Binding Proteins
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2436-2447Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Midgley R, Kerr D. Colorectal cancer. Lancet. 1999;353(9150):391-399. doi:10.1016/s0140-6736(98)07127-x
Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2019;144(12):2992-3000. doi:10.1002/ijc.32055
Thanikachalam K, Khan G. Colorectal cancer and nutrition. Nutrients. 2019;11(1):164. doi:10.3390/nu11010164
Zhang X, Zhang H, Shen B, Sun XF. Chromogranin-a expression as a novel biomarker for early diagnosis of colon cancer patients. Int J Mol Sci. 2019;20(12): 2919. doi:10.3390/ijms20122919
Vassos N, Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. doi:10.1007/s11864-018-0563-8
Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139-4147. doi:10.1002/cncr.32163
Hentze MW, Castello A, Schwarzl T, Preiss T. A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018;19(5):327-341. doi:10.1038/nrm.2017.130
Chatterji P, Rustgi AK. RNA binding proteins in intestinal epithelial biology and colorectal cancer. Trends Mol Med. 2018;24(5):490-506. doi:10.1016/j.molmed.2018.03.008
García-Cárdenas JM, Guerrero S, López-Cortés A, et al. Post-transcriptional regulation of colorectal cancer: a focus on RNA-binding proteins. Front Mol Biosci. 2019;6:65. doi:10.3389/fmolb.2019.00065
Zou C, Wan Y, He L, et al. RBM38 in cancer: role and mechanism. Cell Mol Life Sci. 2021;78(1):117-128. doi:10.1007/s00018-020-03593-w
Cheng G, Ji C, Yang N, Ling M, JJIJoC W, Medicine E. RNA-binding protein RBM38: acting as a tumor suppressor in colorectal cancer. 2016;9(4):7115-7126.
Nussinov R, Zhang M, Tsai CJ, Jang H. Phosphorylation and driver mutations in PI3Kα and PTEN autoinhibition. Mol Cancer Res. 2021;19(4):543-548. doi:10.1158/1541-7786.Mcr-20-0818
Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: a potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol. 2017;39(6):1010428317705754. doi:10.1177/1010428317705754
Zhou XJ, Wu J, Shi L, et al. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer. J Exp Clin Cancer Res. 2017;36(1):149. doi:10.1186/s13046-017-0620-3
Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans. 2008;36(Pt 6):1224-1231. doi:10.1042/bst0361224
Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199-227. doi:10.1146/annurev.pathol.4.110807.092222
Hu R, Zhu X, Chen C, Xu R, Li Y, Xu W. RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs. Cell Prolif. 2018;51(6):e12508. doi:10.1111/cpr.12508
Kuwano Y, Nishida K, Kajita K, et al. Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3'UTR of BCL2 mRNA. Cell Death Differ. 2015;22(5):815-825. doi:10.1038/cdd.2014.176
Wang L, Cui M, Qu F, et al. MiR-92a-3p promotes the malignant progression of hepatocellular carcinoma by mediating the PI3K/AKT/mTOR signaling pathway. Curr Pharm Des. 2021. doi:10.2174/1381612827666210612054156
Jinghua H, Qinghua Z, Chenchen C, et al. MicroRNA miR-92a-3p regulates breast cancer cell Proliferation and Metastasis via regulating B-cell translocation gene 2 (BTG2). Bioengineered. 2021;12(1):2033-2044. doi:10.1080/21655979.2021.1924543
Mao Q, Chen J, Xu W, et al. miR-92a-3p promotes the proliferation and invasion of gastric cancer cells by targeting KLF2. 2020;34(4):1333-1341. doi:10.23812/20-209-a
Huo W, Qi F, KJCci W. Long non-coding RNA FER1L4 inhibits prostate cancer progression via sponging miR-92a-3p and upregulation of FBXW7. Cancer Cell Int. 2020;20:64. doi:10.1186/s12935-020-1143-0
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucl Acids Res. 2019;47(W1):W556-W560. doi:10.1093/nar/gkz430%J
Li J-H, Liu S, Zhou H, Qu L-H, Yang J-H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucl Acids Res. 2013;42(D1):D92-D97. doi:10.1093/nar/gkt1248%J
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C[T]) method. Methods. 2001;25(4):402-408. doi:10.1006/meth.2001.1262
Pang L, Ding J, Ge Y, Fan J, SJAc F. Single-cell-derived tumor-sphere formation and drug-resistance assay using an integrated microfluidics. Anal Chem. 2019;91(13):8318-8325. doi:10.1021/acs.analchem.9b01084
Henry JT, Johnson B. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer. Chin Clin Oncol. 2019;8(5):49. doi:10.21037/cco.2019.08.08
Sagaert X. Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Archiv. 2014;464(3):379-391. doi:10.1007/s00428-013-1532-z
Ye J, Liang R, Bai T, et al. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):212. doi:10.1186/s13046-018-0852-x
Li XX, Shi L, Zhou XJ, et al. The role of c-Myc-RBM38 loop in the growth suppression in breast cancer. J Exp Clin Cancer Res. 2017;36(1):49. doi:10.1186/s13046-017-0521-5
Huang W, Wei XL, Ni W, Cao M, Meng L, Yang H. The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion. Tumour Biol. 2017;39(5):1010428317701635. doi:10.1177/1010428317701635
Qi Y, Liu J, Chao J, et al. PTEN suppresses epithelial-mesenchymal transition and cancer stem cell activity by downregulating Abi1. Sci Rep. 2020;10(1):12685. doi:10.1038/s41598-020-69698-1
Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-1947. doi:10.1126/science.275.5308.1943
Li MF, Guan H, Zhang DD. Effect of overexpression of PTEN on apoptosis of liver cancer cells. Genet Mol Res. 2016;15(2). doi:10.4238/gmr.15028120
Liu J, Ke F, Chen T, et al. MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review. J Cancer Res Clin Oncol. 2020;146(4):809-820. doi:10.1007/s00432-020-03172-3
Li X, Guo S, Min L, Guo Q, Zhang S. miR-92a-3p promotes the proliferation, migration and invasion of esophageal squamous cell cancer by regulating PTEN. Int J Mol Med. 2019;44(3):973-981. doi:10.3892/ijmm.2019.4258
Zeng R, Huang J, Sun Y, Luo J. Cell proliferation is induced in renal cell carcinoma through miR-92a-3p upregulation by targeting FBXW7. Oncol Lett. 2020;19(4):3258-3268. doi:10.3892/ol.2020.11443